Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase?

Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody-positive or ABO blood-type incompatible (ABOi) organ transplantation. Rituximab dramatically improved the outcome of ABOi living-donor liver transplantation (LDLT); however, an effective treatment for posttrans...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transplant Direct
Main Authors: Tajima, Tetsuya, Hata, Koichiro, Okajima, Hideaki, Nishikori, Momoko, Yasuchika, Kentaro, Kusakabe, Jiro, Yoshizawa, Atsushi, Fukumitsu, Ken, Anazawa, Takayuki, Tanaka, Hirokazu, Wada, Seidai, Doi, Junshi, Takaori-Kondo, Akifumi, Uemoto, Shinji
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2019
Assuntos:
Liver Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6791599/
https://ncbi.nlm.nih.gov/pubmed/31723586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TXD.0000000000000932
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados